| DIRECT COMPETITOR COMPARISON | |
| FOLD | Pvt1 | GENZ | SHPGY | Industry | | Market Cap: | 86.51M | N/A | 13.20B | N/A | 104.17M | | Employees: | 115 | 1,6401 | 11,000 | N/A | 63 | | Qtrly Rev Growth (yoy): | 34.50% | N/A | -8.90% | N/A | 19.10% | | Revenue (ttm): | 19.23M | 1.32B1 | 4.61B | N/A | 13.84M | | Gross Margin (ttm): | 8.04% | N/A | 72.40% | N/A | 65.67% | | EBITDA (ttm): | -53.13M | N/A | 1.63B | N/A | -11.86M | | Oper Margins (ttm): | -286.94% | N/A | 26.10% | N/A | -149.46% | | Net Income (ttm): | -53.67M | 124.60M1 | 485.70M | N/A | N/A | | EPS (ttm): | -2.374 | N/A | 1.754 | N/A | -0.31 | | P/E (ttm): | N/A | N/A | 28.36 | N/A | 17.44 | | PEG (5 yr expected): | N/A | N/A | 1.09 | 2.17 | 1.35 | | P/S (ttm): | 4.58 | N/A | 2.87 | N/A | 10.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.54 | 0.03% | 58.24B | 12.55 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 53.70 | 0.56% | 15.53B | 17.97 | | Genzyme Corp. | GENZ | 49.75 | -0.12% | 13.20B | 28.36 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.80 | 0.76% | 39.42B | 16.94 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.43 | -0.11% | 9.35B | 1070.00 | | Teva Pharmaceutical Industries Limited | TEVA | 55.88 | 0.68% | 49.23B | 51.13 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.82 | -0.20% | 4.23B | 20.53 | | King Pharmaceuticals Inc. | KG | 12.31 | 0.00% | 3.06B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.61 | 0.00% | 5.69B | 114.17 | | Pfizer Inc. | PFE | 18.50 | -0.32% | 149.29B | 15.37 | | Johnson & Johnson | JNJ | 64.91 | -0.05% | 179.09B | 14.18 | | GlaxoSmithKline plc | GSK | 42.50 | 0.12% | 107.74B | 13.89 | | Sanofi-Aventis | SNY | 39.77 | -1.34% | 103.84B | N/A | | Novartis AG | NVS | 54.64 | -0.42% | 124.10B | 16.36 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 42.30 | -1.86% | N/A | N/A | | AstraZeneca plc | AZN | 47.00 | 0.82% | 68.15B | 9.44 | | Abbott Laboratories | ABT | 54.54 | 0.52% | 84.36B | 14.78 | | Bristol-Myers Squibb Co. | BMY | 25.61 | 0.31% | 50.73B | 13.25 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | GENZ | | Isis Gains from Teva-OncoGenex Deal
Tue 10:47am -
Zacks.com | | • | GENZ | | Workers Without Kids Deserve Perks Too
Tue 7:16am -
at TheStreet.com | | • | GENZ | | Shire Seeks FDA Approval
Mon, Dec 28 -
Zacks.com | | • | GENZ | | Large-Cap Biotechs Face Familiar Problem
Thu, Dec 24 -
Investor's Business Daily | | • | GENZ | | 20 High-Quality, Cheap Stocks for Last-Minute Shoppers
Thu, Dec 24 -
Morningstar.com | | • | GENZ | | Teva Deal a Reality Check for OncoGenex Investors
Thu, Dec 24 -
at Seeking Alpha | | • | SHPGY | | SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Wed, Dec 23 -
EDGAR Online | | • | GENZ | | 2009 Biotech Cheers and Jeers
Tue, Dec 22 -
at Motley Fool | | • | GENZ | | FDA to issue decision on Shire's Gaucher drug
Tue, Dec 22 -
at MarketWatch | | • | SHPGY | | Shire applies for U.S. approval for Fabry drug
Tue, Dec 22 -
at MarketWatch | | • | SHPGY | | Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Tue, Dec 22 -
PR Newswire | | • | SHPGY | | Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
Mon, Dec 21 -
PR Newswire | | | All Headlines for these symbols... |
|
|
|
0.03% Nasdaq 
0.07 (1.80%) 
Competitors
